Serum Institute of India to acquire stake in IntegriMedical

IntegriMedical's N-FIS technology employs a high-velocity jet stream to administer drugs and biologics.

Vaccine manufacturer the Serum Institute of India (SII) has announced plans to make a strategic investment in IntegriMedical, acquiring a stake of 20%, to progress the development of needle-free injection system (N-FIS) technology.

The investment aligns with SII’s strategy to enhance patient compliance, lower needle-stick injuries and improve the efficacy of liquid medications.

N-FIS technology employs a mechanically powered high-velocity jet stream to administer drugs and biologics.

The system is designed to offer a pain-free experience to patients, particularly those with needle phobia, making the process of medication administration more pleasant and stress-free.

N-FIS has secured regulatory approvals in India, Europe and the US. It holds International Organisation for Standardisation 13485 certification and a US patent.

 

Read more@ https://www.pharmaceutical-technology.com/news/serum-institute-of-india-integrimedical/?cf-view




Comments

Popular posts from this blog

Intramuscular Injections

Intramuscular Injections: The Future of Pain-Free Vaccinations

Subcutaneous Injections